Inactive Instrument

Press Releases LYSOGENE

Equities

LYS

FR0013233475

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

Fragile X Syndrome Pipeline, Clinical Trials Studies, Agreements & Collaborations, and Latest News 2023 (Updated)	23-10-10	AQ
Fragile X Syndrome Pipeline, Clinical Trials and NDA Approvals 2023 (Updated)	23-09-18	AQ
LYSOGENE : Inside Information / News release on accounts, results	23-04-29	PU
LYSOGENE : Inside Information / Operations of the issuer (acquisitions, sales...)	22-12-06	PU
Lysogene : Announces Favorable DSMB Review Recommending Study Continuation and Positive Biomarker Data in Stage 1 of Adaptative Clinical Trial with LYS-GM101 Gene Therapy in GM1 Gangliosidosis	22-11-29	PU
Lysogene to Provide Updates and Topline Results from Phase 2/3 AAVance Gene Therapy Clinical Study and Host Webcast on Wednesday November 23, 2022	22-11-21	AQ
LYSOGENE : Inside Information / Other news releases	22-11-18	PU
LYSOGENE : Half-year liquidity contract statement for LYSOGENE	22-07-11	PU
Lysogene : Provides Additional Update on AAVance Phase 2/3 Gene Therapy Clinical Trial with LYS-SAF302 in children with MPS IIIA	22-07-07	PU
Lysogene : Annual Ordinary and Extraordinary General Meeting of 24 June 2022 Availability of the Preparatory Documents	22-06-03	PU
LYSOGENE : Quarterly financial reporting / First quarter financial report	22-04-28	PU
LYSOGENE : Inside Information / Other news releases	22-04-21	PU
LYSOGENE : Terms of availability of a registration document or its updates	22-04-20	PU
LYSOGENE : Inside Information / Information on annual revenues	22-01-27	PU
Lysogene : Announces First Patient in the United States Dosed with LYS-GM101 Investigational Gene Therapy for the Treatment of GM1 Gangliosidosis	21-08-30	PU
LYSOGENE : Meeting Notice of the Annual Ordinary and Extraordinary General Meeting to be held on 25 June 2021	21-05-20	PU
LYSOGENE : 2020 annual report of liquidity contract	21-04-19	PU
Lysogene : Reports its Cash Position as of 31 December 2020	21-02-17	BU
Lysogene : Reports LYS-SAF302 Biomarker Data Presented at the WORLDSymposium™ 2021	21-02-15	BU
Lysogene : Receives FDA Clearance of Investigational New Drug Application to Initiate the Gene Therapy Clinical Trial in the US with LYS-GM101 for the Treatment of GM1 Gangliosidosis	21-02-12	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases LYSOGENE

Equities

LYS

FR0013233475

Press Releases

Filters